i dont see every patient with ALS taking this drug. only pba patinet will take it. remember 50 % of als has PBA. for MS which is larger population, if company does promote for pain also under the table than it may see better sell. depends on how company promotes and how doctors want to precribe in MS patiets.
the bigger picture is stroke, TBI(BRain injury) Including veterens and parkinsons patients. who make the major portion of sell for neudexta. if they can penetrate these three market well, things will be very rosy for AVNR. GOD knows time will tell. but i cetainly think $ 15 target by jeffery is not a pump at all given the potential for this drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.